Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy

Journal of Urology

Volumn 160, Issue 5, 1998, Pages 1748-1753

  Rogers, Rodman ^a,b   Grossfeld, Gary D ^a,b   Roach III, Mack ^a,b   Shinohara, Katsuto ^a,b   Presti Jr , Joseph C ^a,b   Carroll, Peter R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Prostate specific antigen; Prostatectomy; Radiation

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; HUMAN; MALE; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0011208751     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62398-X     Document Type: Article

References (28)

1. Fair, W. R., Aprikian, A. G., Cohen, D., Sogani, P. and Reuter, V.: Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clin. Invest. Med., 16: 6, 516, 1993.
2. Osterling, J. E., Chan, D. W., Epstein, J. I., Kimball, A. W., Jr., Bruzek, D. J., Rock, R. C., Brendler, C. B. and Walsh, P. C.: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol., 139: 766, 1988.
3. Cox, D. R.: Regression models and life tables. J. Roy. Stat. Soc., 34: 187, 1972.
4. Cox, D. R. and Oakes, D.: Analysis of Survival Data. London: Chapman and Hall, p. 123, 1984.
5. Harrell, F. E. and Lee, K. L.: Verifying assumptions of the Cox proportional hazards model. Presented at the 1st Annual SAS User's Group International Conference. SAS Institute, Cary, North Carolina, 1986.
6. Andriole, G. L. and Catalona, W. J.: Using PSA to screen for prostate cancer. The Washington University experience. Urol. Clin. N. Amer., 20: 647, 1993.
7. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Prostate specific antigen after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol. Clin. N. Amer., 20: 713, 1993.
8. Catalona, W. J. and Smith, D. S.: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol., 152: 1837, 1994.
9. Walsh, P. C., Partin, A. W. and Epstein, J. I.: Cancer and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J. Urol., 152: 1831, 1994.
10. Partin, A. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E., Scardino, P. T. and Pearson, J. D.: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. J.A.M.A., 277: 1445, 1997.
11. Paulson, D. F.: Impact of radical prostatectomy in the management of clinically localized disease. J. Urol., 152: 1826, 1994.
12. Epstein, J. I., Partin, A. W., Sauvageot, J. and Walsh, P. C.: Prediction of progression following radical prostatectomy: A multivariate analysis of 721 men with long-term follow-up. Amer. J. Surg. Path., 20: 286, 1996.
13. Ohori, M., Wheller, T. M., Kattan, M. W., Goto, Y. and Scardino, P. T.: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol., 154: 1818, 1995.
14. Watson, R. B., Civantos, F. and Soloway, M. S.: Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Urology, 48: 80, 1996.
15. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Schnall, M., Tomaszewski, J. E. and Wein, A.: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J. Urol., 154: 131, 1995.
16. McCarthy, J. F., Catalona, W. J. and Hudson, M. A.: Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. J. Urol., 151: 1575, 1994.
17. Coetzee, L. J., Hars, V. and Paulson, D. F.: Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology, 47: 232, 1996.
18. Petrovich, Z., Lieskovsky, G., Freeman, J., Luxton, G., Groshen, S., Formenti, S., Baert, L., Chen, S. C. and Skinner, D. G.: Surgery with adjuvant irradiation in patients with pathologic stage C adenocarcinoma of the prostate. Cancer, 76: 1621, 1995.
19. Zietman, A. L., Coen, J. J., Shipley, W. U. and Althausn, A. F.: Adjuvant irradiation after radical prostatectomy for carcinoma of the prostate: analysis of freedom from PSA failure. Urology, 42: 292, 1993.
20. Krongrad, A., Lai, H. and Lai, S.: Survival after radical prostatectomy. J.A.M.A., 278: 44, 1997.
21. Schild, S. E., Buskirk, S. J., Wong, W. W., Halyard, M. Y., Swanson, S. K., Novicki, D. E. and Ferrigni, R. G.: The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J. Urol., 156: 1725, 1996.
22. Hudson, M. A. and Catalona, W. J.: Effect of adjuvant radiation therapy on prostate specific antigen following radical prostatectomy. J. Urol., 143: 1174, 1990.
23. Lange, P. H., Lightner, D. J., Medini, E., Reddy, P. K. and Vessalla, R. L.: The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J. Urol., 144: 927, 1990.
24. Link, P., Freiha, F. S. and Stamey, T. A.: Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J. Urol., 145: 532, 1991.
25. Schild, S. E., Wong, W. W., Grado, G. L., Buskirk, S. J., Robinow, J. S., Frick, L. M. and Ferrigini, R. G.: Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin. Proc., 69: 613, 1994.
26. Wu, J. J., King, S. C., Montana, G. S., McKinstry, C. A. and Anscher, M. S.: The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostatespecific antigen. Int. J. Rad. Oncol. Biol. Phys., 32: 317, 1995.
27. Syndikus, I., Pickles, T., Kostashuk, E. and Sullivan, L. D.: Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. J. Urol., 155: 1983, 1996.
28. vander Kooy, M. J., Pisansky, T. M., Cha, S. S. and Blute, M. L.: Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology, 49: 65, 1997.